Trobix Bio

Phage-based Antimicrobial Resistance-sensitizing Solutions

Health Tech & Life Sciences
Non Active, Sep 2025 ceased to operate
Series A Netanya, Israel Founded 2019
LinkedIn
Last updated 2026-06-18
Total raised
$8.2M
Last: 2023-03
Stage
Series A
Founded
2019
Headcount
6
HQ
Netanya, Israel
Sector
Health Tech & Life Sciences

About

Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.

Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.

Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.

Funding history · 4 rounds · $8.2M total

2023-03
2020-07
2019-09
Grant Undisclosed
Israel Innovation Authority
2019-03

Q&A

What is Trobix Bio's primary focus?
Trobix Bio is an Israeli biotech company focused on pioneering the field of human microbiome. It utilizes its TBX™ technology platform, which incorporates CRISPR, phage, and synthetic biology, to develop orally administered precision oncology therapeutics.
What is the current status of Trobix Bio?
Trobix Bio is currently inactive, having ceased operations in September 2025.
When was Trobix Bio founded?
Trobix Bio was founded in March 2019.
What are Trobix Bio's preclinical products designed to do?
Trobix Bio's preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. The goal is to allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.
What is Trobix Bio's total funding to date?
Trobix Bio has raised a total of $8.2 million USD.
When was Trobix Bio's most recent funding round and who participated?
Trobix Bio's most recent funding round occurred in March 2023, with The Chartered Group participating.
How many employees does Trobix Bio have?
Trobix Bio has 1-10 employees.
Who is the Co-founder and CEO of Trobix Bio?
Adi Elkeles is the Co-founder and CEO of Trobix Bio.

Team · 1

Adi Elkeles
Founder · Co-founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

therapeuticsinfectiondrug-discoveryantibioticspharmaceuticalspatent-pendingprecision-medicinenanotechnologybioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)